Design Therapeutics, Inc. (DSGN) Q2 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to Design's conference call. At this time, all participants are in a listen-only mode. There will be a question and answer session after the prepared remarks, and please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Dr. Shawn Jeffries, Chief Operating Officer of Design Therapeutics. Sir, you may begin. Thank you. Welcome, and thank you to everyone for joining us today. We are pleased to share with you these initial results from our phase one multiple ascending dose study of DT216 for the treatment of Friedreich ataxia. Earlier today, we issued a press release outlining initial data from this study. The slides that we'll be using during today's call will be available along with a recording of this call in the investor section of our website at designtx.com. With me on the call today are President and CEO Joao Sifert and Chief Medical Officer Dr. Jae Kim. During this call, we will be using forward-looking statements related to our current expectations and plans, including our program development plans, which are subject to risks and uncertainties. Actual results may differ materially due to various important factors, including those described in the risk factor section of our most recently filed 10-Q. These statements represent our views as of this call and should not be relied upon as representing our views as of any date in the future, and we undertake no obligation to publicly update any forward-looking statements. On slide three, serious inherited degenerative diseases affect millions of people across the globe, and research has identified nucleotide repeats in the genome as the underlying cause of a number of these diseases. However, there are currently no therapeutic opt...